HER2-low Education and Resources

Recent advances in research are leading to new approaches for the diagnosis and clinical management of patients with breast cancer. ASCP is dedicated to helping ensure you stay abreast of the latest clinical practice recommendations and best practices to ensure optimal diagnosis, testing, and treatment for patients with breast cancer.

Microlearning

Challenges in Testing Across the HER2+ Breast Cancer Spectrum

This CME/CMLE-accredited, case-based microlearning activity is designed to help pathologists and laboratory professionals increase their knowledge, skills, and competence in testing and diagnosing breast cancer across the HER2 spectrum.

Every few days, participants will be emailed or sent several questions through the Qstream app. Each question consists of an authentic patient case/scenario and an assessment question with 3-5 multiple-choice answers designed to help you make an appropriate diagnosis/recommendation.

The activity offers 1.0 CME/CMLE credit.

This course allows you to claim credit once you have completed the microlearning education in QStream and received your completion notice via email. Do not attempt to claim credit until you have completed the microlearning education in QStream.

Visit ASCP’s Qstream site at https://ascp.qstream.com/.
Sign up for a Qstream account.
Enroll in the case-based microlearning series "Challenges in Testing Across the HER2+ Breast Cancer Spectrum."

Online Modules and Podcasts

Evolving and Emerging Trends in HER2 Classification and Reporting in Breast Cancer

During this recorded 2022 ASCP Annual Meeting session, a moderated expert faculty panel discussed evolving and emerging trends in breast cancer classification and reporting across the HER2+ spectrum. They also discussed how pathologists and laboratory professionals can prepare for HER2-low classification, tracking, and reporting. In addition, they reviewed some of the current challenges in HER2 testing and explored opportunities to prepare for the future landscape of HER classification in breast cancer.

Virtual Tumor Board #1: The Science of HER2-low Breast Cancer and Implications for the Pathology Team

This virtual tumor board from ASCP will help you understand the science and emerging evidence around HER2-low breast cancer, as well as changes to practice that will be necessary in preparation for anticipated approvals of HER2-low breast cancer therapies.

Virtual Tumor Board #2: HER2 Testing in Breast Cancer: Improving IHC Performance

This virtual tumor board from ASCP will help you understand the latest evidence regarding HER2-low breast cancer, HER2 testing guidelines, the implications for the pathology team as HER2-low therapies emerge, and ways to streamline communications with oncologists and other members of the cancer care team.

Twitter Chats

ASCP is hosting a CME/CMLE-accredited Twitter Chat series designed to help pathologists, laboratory professionals, and other members of the cancer care team gain an understanding of the latest evidence regarding HER2-low breast cancer and HER2 testing guidelines.

Each Twitter Chat offers 1 CME/CMLE credit.

MAY 18 TWITTER CHAT

Claim Credit

JUNE 15 TWITTER CHAT

Claim Credit

Tweetorials

ASCP is hosting a CME/CMLE-accredited Tweetorial series designed to help pathologists, laboratory professionals, and other members of the cancer care team gain an understanding of the latest evidence regarding HER2-low breast cancer and HER2 testing guidelines.

Each Tweetorial offers 0.5 CME/CMLE credits.

Tweetorial 1: HER2-low Emerges as a New Classification

This Tweetorial addresses updates from the latest clinical studies on HER2-low breast cancer, HER2-low definition and classification, the clinical implications of HER2-low for the cancer care team, and tools and resources for pathologists.

View on Twitter Download PDF Claim Credit

Tweetorial 2: Examining the Implications of HER2-low

This Tweetorial covers HER2-low breast cancer, HER2-low classification, the clinical implications of HER2-low for the cancer care team, and tools and resources for pathologists.

View on Twitter Download PDF Claim Credit

Tweetorial 3: HER2 Intratumoral Heterogeneity

This Tweetorial will cover the following topics: HER2-low breast cancer, HER2-low classification, and HER2 intratumoral heterogeneity.

View on Twitter Download PDF Claim Credit

Tweetorial 4: HER2 Equivocal and HER2-low

This Tweetorial covers HER2-low breast cancer, HER2-low classification, the clinical implications of HER2-low for the cancer care team, and tools and resources for pathologists.

View on Twitter Download PDF Claim Credit

Tweetorial 5: Disparities in Care and Updates in HER2-low

This Tweetorial will cover the following topics: disparities in breast cancer care and updates in HER2-low breast cancer.

View on Twitter Download PDF Claim Credit

Tweetorial 6: Optimizing Communication when HER2 Expression is Low

This Tweetorial will cover the following topic: ways to optimize communication when HER2 expression levels are low.

View on Twitter Claim Credit

Resources and Tools

Implementation Guide: Preparing for a New Era: A HER2-low Breast Cancer Implementation Guide

This guide is designed to help pathologists, laboratory professionals, and other members of the cancer care team implement changes in clinical practice needed in this emerging era of “HER2-low” breast cancer.

This activity offers 1.0 CME/CMLE credit.

View Guide Claim Credit

Downloadable Slide Deck: HER2-low Breast Cancer

This downloadable, easily sharable set of slides is intended for pathologists to use to educate colleagues on HER2-low breast cancer. The slides cover the following topics:

The science of HER2-low breast cancer
Clinical practice guidelines for HER2 testing in patients with breast cancer
Emerging therapies designed to treat patients with HER2-low breast cancer

Download Here

Pathology Trailblazers

Pathology Trailblazers is a unique leadership development program developed in collaboration with Q Synthesis LLC. The program uses case studies and facilitated discussion to build leadership skills and support the dissemination and implementation of best practices.

As part of the program, each learner developed and implemented a “leadership growth activity” to improve HER2 testing and reporting in breast cancer.

To learn more about how the participants implemented their action plans, please view the project summaries below.

Download Project Summary Report

Acknowledgements and Support

Provided by ASCP in partnership with Q Synthesis, LLC and Clinical Care Options, LLC.

These activities and resources were funded by independent educational grants from AstraZeneca Pharmaceuticals and Daiichi Sankyo, Inc.

Callback Request

Name		*
Country Code		*
Phone Number		*
Scheduled Date		*
Scheduled Time		*
Customer Id

First Name		*
Last Name		*
Email		*
Customer ID